Table 5.

Planar Imaging/SPECT - Comparison of the median values from this study with published data (NDRL in MBq).

Examination type	Patient data this study mean/median	NDRL Austria old (2010) [19]	NDRL Switzerland (2018) [13]	NDRL Germany (2021) [37]	Proposed NDRL Croatia (2020) [15] (Median)	EU (2014) [14]
Brain imaging: I-123 benzamide, beta-CIT	181/185	185		180
Salivary gland scan: Tc-99m pertechnetate	162/157	110			400 (369)
Thyroid imaging: Tc-99m pertechnetate	76/76	110	75	70	200 (185)	80
Thyroid whole body imaging: I-131 sodium iodide	178/185				185 (185)
Parathyroid imaging: Tc-99m isonitrile	465/400	740	550	550	710 (555)
Myocardial perfusion imaging: Tc-99m isonitrile 1-day protocol (rest and stress)	1108/1084	1200	1200	total: 1000	1390 (1184)	1200
Myocardial perfusion imaging: Tc-99m isonitrile 2-day protocol (rest and stress)	total: 1085/1000	740 per day	600 per day, 1200 total	400 per application	730 (634)
Myocardial perfusion/vitality imaging: TI-201 chloride	129/100	110	100			110
Lung perfusion imaging: Tc-99m macroaggregates	128/126	150	180	160	180 (140)	150
Gastric imaging: Tc-99m marked chyme	51/41	110
Renal imaging: Tc-99m MAG3/EC	101/98	110	100	100	150 (137)	100
Renal imaging: Tc-99m DMSA	109/98	110	120		130 (122)
Renal imaging: Tc-99m DTPA	222/223	185			150 (130)
Adrenal imaging: I-123 MIBG	288/260	200
Bleeding: Tc-99m pertechnetate, erythrocytes	565/556	740	750
Inflammation imaging: Tc-99m anti-granulocytes antibodies	688/700	740	800		780 (582)
SNL lymphoscintigraphy: Tc-99m colloid – 1-day protocol	123/98		Total: 80	40	60 (19)
SNL lymphoscintigraphy: Tc-99m colloid – 2-day protocol	119/136			150
Bone imaging: Tc-99m bisphosphonate	652/663	740	700	8 MBq/kg	740 (663)	600
Tumour/inflammation/receptor imaging: In-111 somatostatin receptor antagonist	172/160		180	150
Tumour/inflammation/receptor imaging: Tc-99m somatostatin receptor antagonist	751/740		700	750	740 (740)
Tumour/inflammation/receptor imaging: Tc-99m PSMA	635/607